Intestinal Research

Amarender Singh Puri

4 Articles

IBD

Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study: Anurag Mishra, Amarender Singh Puri, Sanjeev Sachdeva, Ashok Dalal; Intest Res 2022;20(4):445-451. Published online February 8, 2022; DOI: https://doi.org/10.5217/ir.2021.00106

Background/Aims
Response to vaccine in patients with inflammatory bowel disease is lower than in the general population. We aimed to evaluate the efficacy of hepatitis B virus (HBV) vaccination in patients with ulcerative colitis (UC) versus controls.
Methods
We prospectively compared antibody response to HBV vaccination in 100 patients with UC versus controls. HBV vaccination was given to all the cases and controls at 0, 1 and 6 months. Anti-hepatitis B surface (anti-HBs) titers were then measured 4 weeks after the first and the third dose. Adequate immune response (AIR) was considered if the anti-HBs titer was >10 IU/L and effective immune response (EIR) if the anti-HBs titer was >100 IU/L.
Results
Median anti-HBs titer was lower in patients with UC than controls (67 IU/L vs. 105 IU/L, P<0.01). AIR and EIR were significantly lower in patients than in controls (82% vs. 96%, P=0.001; 41% vs. 66%, P<0.001, respectively). Univariate analysis showed that age <30 years, mild to moderate severity of disease, disease duration <5 years, male sex, post first dose anti-HBs titer >2 IU/L and non-exposure to corticosteroids, azathioprine and biologicals were predictors of AIR in patients with UC (P<0.05). Multivariate analysis revealed that only non-exposure to corticosteroids, azathioprine and biologicals, male sex, and disease duration <5 years were independent predictors of AIR.
Conclusions
Response rate to the HBV vaccination in patients with UC was significantly lower as compared to the controls. Male sex, shorter disease duration, and non-exposure to immunomodulators were independent predictors of AIR.

Citations

Citations to this article as recorded by

Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases
Rupert W. Leong, Anthony Sakiris, Arteen Arzivian, John David Chetwood, Thanaboon Chaemsupaphan, Miles P. Sparrow, Michael A. Kamm, Viraj Kariayawasam
Alimentary Pharmacology & Therapeutics.2025; 61(1): 132. CrossRef
Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study
Mohammad Shehab, Fatema Alrashed, Munerah Alyaseen, Zainab Safar, Tunrayo Adekunle, Ahmad Alfadhli, Talat Bessissow
Vaccines.2024; 12(4): 364. CrossRef
Beyond the survey, to the ideal therapy for Asian
Ki Jae Jo, Jong Pil Im
Intestinal Research.2023; 21(3): 280. CrossRef

4,902 View
481 Download
3 Web of Science
3 Crossref

Inflammatory Bowel Diseases

Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry: Ajit Sood, Kirandeep Kaur, Ramit Mahajan, Vandana Midha, Arshdeep Singh, Sarit Sharma, Amarender Singh Puri, Bhabhadev Goswami, Devendra Desai, C. Ganesh Pai, Kiran Peddi, Mathew Philip, Rakesh Kochhar, Sandeep Nijhawan, Shobna Bhatia, N. Sridhara Rao; Intest Res 2021;19(2):206-216. Published online July 13, 2020; DOI: https://doi.org/10.5217/ir.2019.09169

Abstract PDF PubReader ePub

Background/Aims
The national registry for inflammatory bowel disease (IBD) was designed to study epidemiology and prescribing pattern of treatment of IBD in India.
Methods
A multicenter, cross-sectional, prospective registry was established across four geographical zones of India. Adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) were enrolled between January 2014 and December 2015. Information related to demographics; disease features; complications; and treatment history were collected and analyzed.
Results
A total of 3,863 patients (mean age, 36.7 ± 13.6 years; 3,232 UC [83.7%] and 631 CD [16.3%]) were enrolled. The majority of patients with UC (n = 1,870, 57.9%) were from north, CD was more common in south (n = 348, 55.5%). The UC:CD ratio was 5.1:1. There was a male predominance (male:female = 1.6:1). The commonest presentation of UC was moderately severe (n = 1,939, 60%) and E2 disease (n = 1,895, 58.6%). Patients with CD most commonly presented with ileocolonic (n = 229, 36.3%) inflammatory (n = 504, 79.9%) disease. Extraintestinal manifestations were recorded among 13% and 20% of patients in UC and CD respectively. Less than 1% patients from both cohorts developed colon cancer (n = 26, 0.7%). The commonly used drugs were 5-aminosalicylates (99%) in both UC and CD followed by azathioprine (34.4%). Biologics were used in only 1.5% of patients; more commonly for UC in north and CD in south.
Conclusions
The national IBD registry brings out diversities in the 4 geographical zones of India. This will help in aiding research on IBD and improving quality of patient care.

Citations

Citations to this article as recorded by

Diverse Phenotypes, Consistent Treatment: A Study of 30 997 South Asian and White Inflammatory Bowel Disease Patients Using the UK Inflammatory Bowel Disease BioResource
Sharmili Balarajah, Laura Martinez-Gili, James Leslie Alexander, Benjamin Harvey Mullish, Robert William Perry, Jia V Li, Julian Roberto Marchesi, Miles Parkes, Timothy Robin Orchard, Lucy Charlotte Hicks, Horace Richard Timothy Williams
Journal of Crohn's and Colitis.2025;[Epub] CrossRef
Inflammatory bowel disease in south Asia: a scoping review
Shabari Shenoy, Anuraag Jena, Carrie Levinson, Vishal Sharma, Parakkal Deepak, Tina Aswani-Omprakash, Shaji Sebastian, Jean-Frederic Colombel, Manasi Agrawal
The Lancet Gastroenterology & Hepatology.2025; 10(3): 259. CrossRef
Comparison of 1‐Year Clinical Course in Patients With Newly Diagnosed Inflammatory Bowel Disease Between Vietnam and Korea: A Multinational, Multicenter Retrospective Cohort Study
Luan Minh Dang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Hoang Huu Bui, Chuong Dinh Nguyen, Chi Thi Nguyen, Nam Hoai Nguyen, Hien Thi‐Thu Nguyen, Nga Thi Dinh, Lien Thi‐Phuong Nguyen, Khien Van Vu, Minh Cuong Duong
JGH Open.2025;[Epub] CrossRef
Burden of inflammatory bowel disease in India: analysis of the Global Burden of Disease study from 1990 to 2019
Suprabhat Giri, Anuraag Jena, Praveen Kumar-M, Jaikumar Rajavoor Muniswamy, Preetam Nath, Vishal Sharma
Intestinal Research.2025;[Epub] CrossRef
Dietary essential oil components: A systematic review of preclinical studies on the management of gastrointestinal diseases
Rajiv Gandhi Gopalsamy, Poovathumkal James Antony, Kumaraswamy Athesh, Varghese Edwin Hillary, Monalisa Martins Montalvão, Govindasamy Hariharan, Lucas Alves da Mota Santana, Lysandro Pinto Borges, Ricardo Queiroz Gurgel
Phytomedicine.2025; 140: 156630. CrossRef
FoxP3-positive T regulatory cells and its effector mechanisms in Crohn’s disease: an immunohistochemical and image morphometric analysis on endoscopic mucosal biopsies
Susama Patra, Shalini Chaudhary, Subash Chandra Samal, Pavithra Ayyanar, Somanath Padhi, Hemanta Kumar Nayak, Amit Kumar Satapathy, Saurav Nayak, Ajit Sahu, Tapaskanti Parida, Mohammed Shahin
European Journal of Gastroenterology & Hepatology.2025;[Epub] CrossRef
Global prevalence of biologic drugs use in inflammatory bowel diseases: a systematic review and meta-analysis
Caroline Tianeze de Castro, Douglas da Silva Oliveira, Fabrício Freire de Melo, Mauricio Lima Barreto, Carlos Antonio de Souza Teles Santos, Djanilson Barbosa dos Santos
Scandinavian Journal of Gastroenterology.2025; : 1. CrossRef
Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial
Arshdeep Singh, Manjeet Kumar Goyal, Vandana Midha, Ramit Mahajan, Kirandeep Kaur, Yogesh Kumar Gupta, Dharmatma Singh, Namita Bansal, Ramandeep Kaur, Shivam Kalra, Omesh Goyal, Varun Mehta, Ajit Sood
American Journal of Gastroenterology.2024; 119(7): 1365. CrossRef
Clinical profile of patients with ulcerative colitis- A hospital based study from Madhya Pradesh
Mayank Jain
Indian Journal of Gastroenterology.2024; 43(1): 274. CrossRef
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye
Intestinal Research.2023; 21(1): 137. CrossRef
Gender Differences in Psychological Symptoms and Quality of Life in Patients with Inflammatory Bowel Disease in China: A Multicenter Study
Chuan Liu, Jixiang Zhang, Min Chen, Ping An, Jiankang Xiang, Rong Yu, Suqi Zeng, Shuchun Wei, Beiying Deng, Zhongchun Liu, Changqing Jiang, Jie Shi, Kaichun Wu, Weiguo Dong
Journal of Clinical Medicine.2023; 12(5): 1791. CrossRef
Clinical and magnetic resonance imaging spectrum of complex perianal fistulizing Crohn’s disease: A cohort study from northern India
Arshdeep Singh, Chandan Kakkar, Shreya Garg, Kirti Arora, Vandana Midha, Ramit Mahajan, Satpal Singh Virk, Narender Pal Jain, Dharmatma Singh, Kriti Sood, Ashish Tripathi, Dhruv Gupta, Ishita Gupta Kaushal, Ritu Dhawan Galhotra, Kavita Saggar, Ajit Sood
Indian Journal of Gastroenterology.2023; 42(5): 668. CrossRef
Is disease activity associated with social support and psychological distress in Crohn’s disease patients? Results of a cross-sectional study in a Chinese hospital population
Mengting Huang, Lei Tu, Linxia Wu, Yan Zou, Xin Li, Xiaofei Yue, Chen Huang, Ping Lei, Qian Li, Ping Han, Lian Yang, Liangru Zhu
BMJ Open.2023; 13(10): e076219. CrossRef
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Sang Hyoung Park
Intestinal Research.2022; 20(2): 159. CrossRef
Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Clostridioides Infection in Patients with Inflammatory Bowel Disease
Mi Rae Lee, Eun Soo Kim
The Korean Journal of Gastroenterology.2022; 80(2): 66. CrossRef
Latent and Active Tuberculosis Infection in Patients with Inflammatory Bowel Disease
Byung Chul Jin, Hee Jin Moon, Sang Wook Kim
The Korean Journal of Gastroenterology.2022; 80(2): 72. CrossRef
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef
What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?
Su Bee Park, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2022; 16(5): 676. CrossRef
Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia
Madhura Balasubramaniam, Neilanjan Nandi, Tina Aswani-Omprakash, Shaji Sebastian, Vishal Sharma, Parakkal Deepak, Shrinivas Bishu, Neha D. Shah, Sumit Bhatia, Tauseef Ali, Sharan Khela, Kiran Peddi
Gastroenterology.2022; 163(5): 1145. CrossRef
Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia
Madhura Balasubramaniam, Neilanjan Nandi, Tina Aswani-Omprakash, Shaji Sebastian, Vishal Sharma, Parakkal Deepak, Shrinivas Bishu, Neha D. Shah, Sumit Bhatia, Tauseef Ali, Sharan Khela, Kiran Peddi
Clinical Gastroenterology and Hepatology.2022; 20(11): 2421. CrossRef
Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study
Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Ge
Gut and Liver.2022; 16(6): 907. CrossRef
Clinical Characteristics of Korean Patients with Elderly-Onset Crohn’s Disease: Results from the Prospective CONNECT Study
You Sun Kim, Min Jeong Na, Byong Duk Ye, Jae Hee Cheon, Jong Pil Im, Joo Sung Kim
Gut and Liver.2022; 16(6): 995. CrossRef
The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
Satimai Aniwan, Priscila Santiago, Edward V. Loftus, Sang Hyoung Park
United European Gastroenterology Journal.2022; 10(10): 1063. CrossRef
Sociodemographic Characteristics, Smoking, and Family History of Patients with Inflammatory Bowel Disease, Northern Part of Iraq
Blnd Ibrahim Mohammed, Bushra Karem Amin
Medical Journal of Babylon.2022; 19(4): 615. CrossRef
Inflammatory bowel diseases in Tamil Nadu: A survey of demographics, clinical profile, and practices
Rohan V Yewale, Kartik Natarajan, Jeyaraj Ubal Dhus, Sarojini Ashok Parameswaran, Kallipatti Ramaswamy Palaniswamy, Doraisamy Babu Vinish, Aravindh Somasundaram, Arulraj Ramakrishnan, Sibithooran Karmegam, Ramaswamy Saraswathy Arun, Ujjani Shankaraiah Man
JGH Open.2021; 5(11): 1306. CrossRef
Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom?
Soo-Young Na, Yun-Jeong Lim
Diagnostics.2021; 11(12): 2240. CrossRef

14,514 View
503 Download
26 Web of Science
28 Crossref

Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis: K Arivarasan, Vaishali Bhardwaj, Sukrit Sud, Sanjeev Sachdeva, Amarender Singh Puri; Intest Res 2016;14(4):365-368. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.365

Abstract PDF PubReader

Pyoderma gangrenosum (PG) is an uncommon extra-intestinal manifestation of inflammatory bowel disease (IBD). Despite limited published literature, biologics have caused a paradigm shift in the management of this difficult-to-treat skin condition. The clinical data and outcomes of three patients with active ulcerative colitis and concurrent PG treated with biologics (infliximab two and adalimumab one) are reviewed in this report. Biologics were added because of the sub-optimal response of the colonic symptoms and skin lesions to parenteral hydrocortisone therapy. All three patients showed a dramatic response to the addition of the biologics. In view of the rapid healing of the skin lesions, superior response rate, and the additional benefit of improvement in the underlying colonic disease following treatment, anti-tumor necrosis factor blockers should be considered as a first line therapy in the management of PG with underlying IBD.

Citations

Citations to this article as recorded by

Multiple extraintestinal manifestations in a patient with acute severe ulcerative colitis: a case report
Eun Young Park, Dong Hoon Baek, Seung Min Hong, Geun Am Song
Kosin Medical Journal.2022; 37(4): 361. CrossRef
Effective use of switching biologics for ulcerative colitis complicated with pyoderma gangrenosum and primary sclerosing cholangitis
Kenta Iwahashi, Yuichiro Kuroki, Yuichi Takano, Masatsugu Nagahama
BMJ Case Reports.2021; 14(5): e241744. CrossRef
Treatment of Pyoderma Gangrenosum in Pediatric Inflammatory Bowel Disease
Katherine Vaidy, Rebecca Winderman, Simon S. Rabinowitz, Steven M. Schwarz
JPGN Reports.2020; 1(2): e008. CrossRef
Idiopathic pyoderma gangrenosum or a systemic disease predictor?
Todor Yordanov, Jenya Dimitrova, Ivanka Temelkova, Tsveta Kalinova, Neli Koleva, Sonya Marina
Scripta Scientifica Medica.2020; 52(3): 27. CrossRef
Biologic and small-molecule medications in the management of pyoderma gangrenosum
Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings, Alex G. Ortega-Loayza
Journal of Dermatological Treatment.2019; 30(3): 264. CrossRef
Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review
Hakim Ben Abdallah, Karsten Fogh, Rikke Bech
International Wound Journal.2019; 16(2): 511. CrossRef
Pyoderma gangrenosum successfully treated with golimumab: Case report and review of the literature
Federico Diotallevi, Anna Campanati, Giulia Radi, Valerio Brisigotti, Elisa Molinelli, Donatella Brancorsini, Annamaria Offidani
Dermatologic Therapy.2019; : e12928. CrossRef
A Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe
Medina G. Saffie, Anjali Shroff
Case Reports in Infectious Diseases.2018; 2018: 1. CrossRef
Hyperbaric oxygen therapy for pyoderma gangrenosum associated with ulcerative colitis
Hyun Il Seo, Hyun-Ju Lee, Koon Hee Han
Intestinal Research.2018; 16(1): 155. CrossRef
A RARE CASE OF CROHN DISEASE COMPLICATED WITH STEROID MONOTHERAPY-RELATED RETROPHARYNGEAL ABSCESS AND INITIALLY MISINTERPRETED PYODERMA GANGRENOSUM DEVELOPMENT
Michael Doulberis, Jörg Dähn, Jannis Kountouras, Volker Maier, Arthur Helbling, Patrick Dubach
Gastroenterology Nursing.2018; 41(4): 347. CrossRef
Successful treatment with tacrolimus of refractory pyoderma gangrenosum with pouchitis after restorative proctocolectomy for ulcerative colitis
Miwa Satake, Hirotake Sakuraba, Hiroto Hiraga, Natsumi Tarakita, Yui Akemoto, Shinji Ota, Keisuke Hasui, Daisuke Nishiya, Shiro Hayamizu, Hidezumi Kikuchi, Manabu Sawaya, Daisuke Chinda, Tatsuya Mikami, Tadashi Shimoyama, Shinsaku Fukuda
Immunological Medicine.2018; 41(3): 142. CrossRef

6,404 View
60 Download
8 Web of Science
11 Crossref

Epidemiology of Ulcerative Colitis in South Asia: Amarender Singh Puri; Intest Res 2013;11(4):250-255. Published online October 30, 2013; DOI: https://doi.org/10.5217/ir.2013.11.4.250

Abstract PDF

The South Asian region comprising of India, Pakistan, Bangladesh, Nepal, and Sri Lanka is multi-ethnic with vast cultural differences. Yet they have in common, a strong predisposition for inflammatory bowel disease especially ulcerative colitis (UC). The vast majority of the population is rural with limited access to health care facilities. Community based studies on epidemiology of UC are sparse making it difficult to extrapolate data for the whole region. India has the highest incidence and prevalence of UC in Asia which is higher than the published figures for Korea and Japan, the two leading industrialized countries in Asia. Asian diaspora studies have revealed an unmasking of the disease when natives of this region migrate to countries with a higher prevalence of the disease. Data mainly from the UK suggests a higher incidence of the disease in Asian migrants compared to the indigenous population. Incidence data from within the sub-continent suggests a higher incidence of the disease in India as compared to its southern neighbour Sri Lanka suggesting a north-south gradient. Time trend studies from India do not suggest an increasing incidence of disease as has been observed in other parts of Asia. Some data point to phenotypically different disease in south Asian patients as compared to Caucasians. Familial clustering and cumulative colectomy rates are higher in Western patients as compared to their Asian counterparts. Asian patients with UC have a significantly lower risk of development of colorectal carcinoma vis a vis the Caucasian population. There is a pressing need for more studies on the epidemiology, long-term outcome and natural history of the disease in this region. (Intest Res 2013;11:250-255)

Citations

Citations to this article as recorded by

Short health scale: A valid measure of health-related quality of life in Korean-speaking patients with inflammatory bowel disease
Soo-Kyung Park, Bong Min Ko, Hyeon Jeong Goong, Jeong Yeon Seo, Sang Hyuk Lee, Hae Lim Baek, Moon Sung Lee, Dong Il Park
World Journal of Gastroenterology.2017; 23(19): 3530. CrossRef
Infliximab‐induced tuberculosis in patients with UC: Experience from India—a country with high prevalence of tuberculosis
Amarender S Puri, Devendra Desai, Ajit Sood, Sanjeev Sachdeva
Journal of Gastroenterology and Hepatology.2017; 32(6): 1191. CrossRef
Adsorptive Granulocyte and Monocyte Apheresis in the Treatment of Ulcerative Colitis: The First Multicenter Study in China
Ya-Min Lai, Wei-Yan Yao, Yao He, Xuan Jiang, Yu-Bei Gu, Min-Hu Chen, Yu-Lan Liu, Yao-Zong Yuan, Jia-Ming Qian
Gut and Liver.2017; 11(2): 216. CrossRef
Extent of disease is a major outcome predictor in patients with ulcerative colitis and pregnancy
Amarender Puri, Vaishali Bharadwaj, Sanjeev Sachdeva
Indian Journal of Gastroenterology.2015; 34(2): 108. CrossRef
Colon Cancer Screening and Surveillance in Inflammatory Bowel Disease
Song I Bae, You Sun Kim
Clinical Endoscopy.2014; 47(6): 509. CrossRef

3,301 View
54 Download
5 Crossref

Author index